Navigation Links
Aratana Therapeutics Adds To Drug Development Team
Date:3/26/2013

span>Paris, France from 2000 to 2008.  In 1990, she co-founded PROTOCOLE, the first European veterinary consultancy and contract research organization focused on clinical drug development and regulatory affairs, which was acquired by ICON in 2000.

Primarily focused on transitioning human drugs to meet the needs of veterinary medicine, Dr. Lachaud's work has resulted in significant companion animal health product approvals in Europe and the U.S. in a number of innovative therapeutic areas, including reproduction, atopic dermatitis, chronic heart failure, wound healing, chronic kidney disease, pain, obesity, oncology, cognitive dysfunction and anxiety-related disorders.

As Head of Business and Product Development Europe, her responsibilities include coordinating the European Regulatory process for Aratana's products and running the company's in-licensing and out-licensing activities in Europe.

She received her veterinary degree from Alfort National Veterinary School in Paris and her doctorate in veterinary medicine from the University of Paris, France.

Laura Simon Treml , VMD, Ph.D.
Prior to her appointment at Aratana, Dr. Treml led clinical development programs for dogs and cats and managed the Companion Animal Efficacy group at Bayer Animal Health.  Earlier in her career, she practiced small animal medicine and surgery on the East Coast for nine years.

As Director of Drug Development at Aratana, Dr. Treml's responsibilities include designing and managing several of the company's drug development programs and scientifically evaluating potential new in-licensing drug candidates.

Dr. Treml received both her veterinary degree and her Ph.D. in Immunology from the University of Pennsylvania. 

Glenda L. Armintrout
Prior to jo
'/>"/>

SOURCE Aratana Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Aratana Therapeutics Completes $15 Million Series B Financing
2. Aratana Therapeutics Appoints Craig Tooman to Board of Directors
3. Aratana Therapeutics Adds Product Manufacturing Expertise with the Appointment of Two Senior Executives
4. Aratana Closes $10 Million Non-Dilutive Financing with Square 1 Bank
5. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
6. Nile Therapeutics Reports 2011 Third Quarter Financial Results
7. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
8. Fate Therapeutics Strengthens Its iPSC Platform
9. Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
10. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
11. MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... New York (PRWEB) December 23, 2014 According ... the Long Island Affiliate of ITRA Global, the national office ... but steady recovery. This is evidenced by the third ... strong stock market. Low energy costs have held inflation ... The only negative is the housing market remaining soft. , ...
(Date:12/24/2014)... The report expects global cell isolation and expansion market ... a carefully analyzed data about the vital drivers, restraints, ... Full Copy of Report @ http://bit.ly/1yUxy0T , ... expansion will keep witnessing growth at an impressive CAGR ... driven by rapid technological advancements, government funding and investments, ...
(Date:12/24/2014)... Texas , Dec. 23, 2014 ... company focused on gynecologic disease, announced today that ... Schuler , Birchview Fund LLC and several Vermillion ... of unregistered shares of Vermillion,s common stock and ... stock in a private placement.  ...
(Date:12/24/2014)... Dec. 23, 2014  Rock Creek Pharmaceuticals, Inc., (NASDAQ: ... filed a Clinical Trial Application (CTA) with the ... Agency (MHRA) seeking regulatory approval to initiate clinical trials ... Citrate. Contingent on the Company receiving CTA ... I trial to assess the safety, tolerability and dose ...
Breaking Biology Technology:ITRA Global Reports Long Island Is Out of Sync With The National Office Market 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 3The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3
... , CANTON, Mass. and SAN DIEGO, Oct. 27 ... speak on the first night of the prestigious TEDMED ... Dr. Bates, speech "Where Does Replacement Skin Come From?" ... of Regenerative Medicine and discuss the transformation of patient ...
... Inc., (Soligenix or the Company) (OTC Bulletin Board: SNGX), ... company, announced today that its Chief Financial Officer Evan ... at the BIO Investor Forum. , The presentation will ... PM PDT at The Palace Hotel in San Francisco, ...
... , NEW YORK, Oct. 27 How does ... based on invention, innovation and entrepreneurship? , (Logo: ... blogging together with real-time celebrity lectures (and required ... anything other universities have ever attempted. , ...
Cached Biology Technology:Dr. Damien Bates of Organogenesis Speaks on Regenerative Medicine for Opening Night of TEDMED Conference 2Soligenix to Present at 8th Annual BIO Investor Forum 2Soligenix to Present at 8th Annual BIO Investor Forum 3Soligenix to Present at 8th Annual BIO Investor Forum 4NYU-Poly Launches Unique Undergrad Forum on Invention, Innovation and Entrepreneurship 2NYU-Poly Launches Unique Undergrad Forum on Invention, Innovation and Entrepreneurship 3NYU-Poly Launches Unique Undergrad Forum on Invention, Innovation and Entrepreneurship 4
(Date:12/19/2014)... , Dec. 18, 2014 Research and Markets ... addition of the "iPhone 5S Fingerprint Sensor ... report to their offering. ... acquisition of AuthenTec in July 2012, Apple introduced ... It is currently the only device of Apple ...
(Date:12/17/2014)... , Dec. 15, 2014 The Defense ... it easier to detect and prevent counterfeit microcircuits ... Today the agency started performing an in-house microcircuit ... validate the authenticity of purchased microcircuits while increasing ... quality control measures will be conducted at DLA,s ...
(Date:12/15/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/87pph8/global_facial ) ... Facial Recognition Market 2015-2019" report to their ... Facial recognition is a technology used ... measures the overall facial feature of a person ... distance between eyes. Facial recognition is used for ...
Breaking Biology News(10 mins):iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology Report 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3
... North America are a growing concern for legislators. Expanded waistlines ... disease and some cancers. One University of Alberta researcher says ... they may find that governments will throw their weight into ... Nola Ries of the Faculty of Law,s Health Law and ...
... a new nanolithography technique that is less expensive than ... with biomedical applications. "Among other things, this type ... use in biological sensors that can identify target molecules, ... medical conditions," says Dr. Albena Ivanisevic, co-author of a ...
... University School of Medicine (BUSM) has shown that a compound ... emphysema and reverse some of the damage caused by the ... cells from patients with emphysema, normal gene activity in altered ... repaired. The study, which is published in BioMed ...
Cached Biology News:Legislated to health? 2Legislated to health? 3Researchers develop new, less expensive nanolithography technique 2BUSM researchers find potential key to halt progression, reverse damage from emphysema 2BUSM researchers find potential key to halt progression, reverse damage from emphysema 3